ERBB2 and gastric adenocarcinoma: Of the 337 patients with gastric adenocarcinoma, 180 (53%) were tested for PD-L1, 199 (59%) were tested for MMR/MSI, and 295 (88%) were tested for HER2 (Table 1 and Table S2).